Improvement of transmucosal absorption of drugs in drug delivery system (DDS) 1. Improvement of intestinal and transmucosal absorption of poorly absorbable drugs: Current status and future prospect

Drug Delivery System

Volumn 20, Issue 4, 2005, Pages 404-415

  Yamamoto, Akira ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

absorption enhancer; chemical in vilification; colon specific drug delivery; intestinal absorption; pulmonary absorption; transmucosal absorption

Indexed keywords

EID: 85010092035     PISSN: 09135006     EISSN: 18812732     Source Type: Journal    
DOI: 10.2745/dds.20.404     Document Type: Article

References (93)

1. Yamamoto A, Luo AM, Dodda-Kashi S, Lee VHL: The ocular route for systemic insulin delivery in the albino rabbit. J Pharmacol Exp Ther 249: 249-255, 1989.
2. Hayakawa E, Yamamoto A, Shoji Y, Lee VHL: Effect of sodium glycocholate and polyoxyethylene-9-lauryl ether on the hydrolysis of varying concentrations of insulin in the nasal homogenates of the albino rabbit. Life Sci 45: 167-174, 1989.
3. Yamamoto A, Hayakawa E, Lee VHL: Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes. Life Sci 47: 2465-2474, 1990.
4. Lee VHL, Yamamoto A: Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Delivery Rev 4: 171-207, 1990.
5. Lee VHL, Yamamoto A, Kompella UB: Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst 8: 91-192, 1991.
6. Hayakawa E, Chien DS, Inagaki K, Yamamoto A, Wang W, Lee VHL: Conjunctival penetration of insulin and peptide drugs in the albino rabbit. Pharm Res 9: 769-775, 1992.
7. Yamamoto A, Hayakawa E, Kato Y, Nishiura A, Lee VHL: A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit. J Pharmacol Exp Ther 263: 25-31, 1992.
8. Muranishi S, Yamamoto A, Okada H: Rectal and Vaginal Absorption of Peptides and Proteins in Biological Barriers to Protein Delivery. (eds. Audus KL et al.), Plenum Press, New York, 1993, 199-227.
9. Okagawa T, Fujita T, Murakami M, Yamamoto A, Shimura T et al.: Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors. Life Sci 55: 677-683, 1994.
10. Sasaki I, Fujita T, Murakami M, Yamamoto A, Nakamura E et al.: Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. 1. Possible factors for the low oral bioavailability in rats. Biol Pharm Bull 17: 1256-1261, 1994.
11. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T et al.: Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 11: 1496-1500, 1994.
12. Muranishi S, Yamamoto A: Mechanisms of Absorption Enhancement through Gastrointestinal Epithelium in Drug Absorption Enhancement - Concepts, Possibilities, Limitations and Trends. (ed. deBoer A), Harwood Academic Publishers, Switzerland, 1994, 67-100.
13. Sasaki I, Tanaka K, Fujita T, Murakami M, Yamamoto A et al.: Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. 2. In situ and in vivo absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull 18: 976-979, 1995.
14. Gotoh S, Nakamura R, Nishiyama M, Fujita T, Yamamoto A et al.: Does bacitracin have an absorption enhancing effect in the intestine? Biol Pharm Bull 18: 794-796, 1995.
15. Gotoh S, Nakamura R, Nishiyama M, Quan YS, Fujita T et al.: Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine. J Pharm Sci 85: 858-862, 1996.
16. Yamamoto A, Uchiyama T, Nishikawa R, Fujita T, Muranishi S: Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: Effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J Pharm Pharmacol 48: 1285-1289, 1996.
17. Uchiyama T, Yamamoto A, Hatano H, Fujita T, Muranishi S: Effectiveness and toxicity screening of various absorption enhancers in the large intestine: Intestinal absorption of phenol red and protein and phospholipid release from the intestinal membrane. Biol Pharm Bull 19: 1618-1621, 1996.
18. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A et al.: Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: Implications in peptide delivery to the colon. J Pharm Pharmacol 49: 164-168, 1997.
19. Sugiyama T, Yamamoto A, Kawabe Y, Uchiyama T, Quan YS et al.: Effects of various absorption enhancers on the intestinal absorption of water soluble drugs by in vitro Ussing chamber method: Correlation with an in situ absorption experiment. Biol Pharm Bull 20: 812-814, 1997.
20. Sasaki I, Tamura T, Shibakawa T, Fujita T, Murakami M et al.: Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms. Pharm Res 14: 1004-1007, 1997.
21. Yamamoto A, Okagawa T, Kotani A, Uchiyama T, Shimura T et al.: Effects of different absorption enhancers on the permeation of ebiratide, an ACTH analogue, across intestinal membranes. J Pharm Pharmacol 49: 1057-1061, 1997.
22. Uchiyama T, Kotani A, Kishida T, Tatsumi H, Okamoto A et al.: Effects of various protease inhibitors on the stability and permeability of (D-Ala2, D-Leu5)enkephalin in the rat intestine: Comparison with leucine enkephalin. J Pharm Sci 87: 448-452, 1998.
23. Quan YS, Hattori K, Lundborg E, Fujita T, Murakami M et al.: Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol Pharm Bull 21: 615-620, 1998.
24. Tozaki H, Odoriba T, Iseki T, Taniguchi T, Fujita T et al.: Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J Pharm Pharmacol 50: 913-920, 1998.
25. Quan YS, Fujita T, Tohara D, Tsuji M, Kohyama M et al.: Transport kinetics of leucine enkephalin across Caco-2 monolayers: Quantitative analysis for contribution of enzymatic and transport barrier. Life Sci 64: 1243-1252, 1999.
26. Sasaki I, Tozaki H, Matsumoto K, Ito Y, Fujita T et al.: Development of an oral formulation of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, using n-lauryl-β-D-maltopyranoside as an absorption enhancer. Biol Pharm Bull 22: 611-615, 1999.
27. Uchiyama T, Sugiyama T, Quan YS, Kotani A, Okada N et al.: Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: Their intestinal mucosal toxicity and absorption enhancing mechanism of n-lauryl-β-D-maltopyranoside. J Pharm Pharmacol 51: 1241-1250, 1999.
28. Yamamoto A, Tatsumi H, Maruyama M, Uchiyama T, Okada N et al.: Modulation of intestinal permeability by nitric oxide donors: Implications in intestinal delivery of poorly absorbable drugs. J Pharmacol Exp Ther 296: 84-90, 2001.
29. Fetih G, Habib F, Okada N, Fujita T, Attia M etl al.: Nitric oxide donors can enhance the intestinal transport and absorption of insulin and (Asu1,7)-eel calcitonin in rats. J Controlled Release, 2005, (in press).
30. Tavelin S, Hashimoto K, Malkinson J, Lazorova L, Toth I et al.: A new principle for tight junction modulation based on occluding peptides. Mol Pharmacol 64: 1530-1540, 2005.
31. Kimura T, Murakawa Y, Ohno M, Ohtani S, Higaki K: Gastrointestinal absorption of recombinant human insulin-like growth factor-I in rats. J Pharmacol Exp Ther 283: 611-618, 1997.
32. Taki Y, Sakane T, Nadai T, Sezaki H, Amidon GL et al.: Gastrointestinal absorption of peptide drug: Quantitative evaluation of the degradation and the permeation of metkephamide in rat small intestine. J Pharmacol Exp Ther 274: 373-377, 1995.
33. Morishita M, Morishita I, Takayama K, Machida Y, Nagai T: Site-dependent effect of aprotinin, sodium caprate, Na2-EDTA and sodium glycocholate on intestinal absorption of insulin. Biol Pharm Bull 16: 68-72, 1993.
34. Utoguchi N, Watanabe Y, Shida T, Matsumoto M: Nitric oxide donors enhance rectal absorption of macromolecules in rabbits. Pharm Res 15: 870-876, 1998.
35. Kotze AF, de Leeuw BJ, LueBen HL, de Boer AG, Verhoef JC et al.: Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers. Int J Pharm 159: 243-253, 1997.
36. Kotze AF, de LueBen HL, Leeuw BJ, de Boer AG, Verhoef JC et al.: N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res 14: 1197-1202, 1997.
37. Nerurkar MM, Burton PS, Borchardt RT: The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 13: 528-534. 1996.
38. Nerurkar MM, Ho NFH, Burton PS, Vidmar TJ, Borchardt RT: Mechanistic roles of neutral surfactants on concurrent polarized and passive transport of a model peptide in Caco-2 cells. J Pharm Sci 86: 813-821, 1997.
39. Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N et al.: Modulation of intestinal P-glycoprotein function by Cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 93: 877-885, 2004.
40. Hashizume M, Douen T, Murakami M, Yamamoto A, Takada K et al.: Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J Pharm Pharmacol 44: 555-559, 1992.
41. Yamada K, Murakami M, Yamamoto A, Takada K, Muranishi S: Improvement of intestinal absorption of thyrotropin-releasing hormone by chemical modification with lauric acid. J Pharm Pharmacol 44: 717-721, 1992.
42. Tenma T, Yodoya E, Tashima S, Fujita T, Murakami M et al.: Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharm Res 10: 1488-1492, 1993.
43. Muranishi S, Yamamoto A: Modification of Peptide for Intestinal Delivery in Topics in Pharmaceutical Sciences 1993. (eds. Crommelin DJA et al.), Medpharm Scientific Publishers, Stuttgart, 1994, 372-382.
44. Asada H, Douen T, Mizokoshi Y, Fujita T, Murakami M et al.: Stability of acyl derivatives of insulin in the small intestine: Relative importance of insulin association characteristics in aqueous solution. Pharm Res 11: 1115-1120, 1994.
45. Yodoya E, Uemura K, Tenma T, Fujita T, Murakami M et al.: Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J Pharmacol Exp Ther 271: 1509-1513, 1994.
46. Asada H, Douen T, Waki M, Adachi S, Fujita T et al.: Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci 84: 682-687, 1995.
47. Setoh K, Murakami M, Araki N, Fujita T, Yamamoto A et al.: Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. J Pharm Pharmacol 47: 808-811, 1995.
48. Fujita T, Fujita T, Morikawa K, Tanaka H, Iemura O et al.: Improvement of intestinal absorption of human calcitonin by chemical modification with fatty acids: Synergistic effects of acylation and absorption enhancers. Int J Pharm 134: 47-57, 1996.
49. Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A et al.: Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim Biophys Acta 1283: 119-126, 1996.
50. Fujita T, Morishita Y, Ito H, Kuribayashi D, Yamamoto A et al.: Enhancement of the small intestinal uptake of phenylalanyl-glycine via a H+/oligopeptide transport system by chemical modification with fatty acids. Life Sci 61: 2455-2465, 1997.
51. Yamamoto A, Muranishi S: Rectal drug delivery systems. Improvement of rectal peptide absorption by absorption enhancers, protease inhibitors and chemical modification. Adv Drug Delivery Rev 28: 275-299, 1997.
52. Fujita T, Kawahara I, Quan YS, Hattori K, Takenaka K et al.: Permeability characteristics of tetragastrin across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors. Pharm Res 15: 1387-1392, 1998.
53. Uchiyama T, Kotani A, Tatsumi H, Kishida T, Okamoto A et al.: Development of novel lipophilic derivatives of DADLE (Leucine enkephalin analogue): Intestinal permeability characteristics of DADLE derivatives in rats. Pharm Res 17: 1461-1467, 2000.
54. Yamamoto A, Setoh K, Murakami M, Shironoshita M, Kobayashi T et al.: Enhanced transdermal delivery of phenylalanyl-glycine by chemical modification with various fatty acids. Int J Pharm 250, 119-128, 2003.
55. Yamamoto A, Morishita Y, Sugishita S, Hayami T, Okada N et al.: Enhanced permeability of phenylalanyl-glycine (Phe-Gly) across the intestinal membranes by chemical modification with various fatty acids. Drug Metab Pharmacokinet 18: 23-32, 2003.
56. Futaki S: Arginin-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharm 245: 1-7, 2002.
57. Tamai I, Nakanishi T, Nakahara H, Sai Y, Ganapathy V et al.: Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J Pharm Sci 87: 1542-1546, 1998.
58. Mizuma T, Ohta K, Koyanagi A, Awazu S: Improvement of intestinal absorption of leucine enkephalin by sugar coupling and peptidase inhibitors. J Pharm Sci 85: 854-857, 1996.
59. Mizuma T, Koyanagi A, Awazu S: Intestinal transport and metabolism of analgesic dipeptide, kyotorphin: ratelimiting factor in intestinal absorption of peptide as drug. Biochim Biophys Acta 1335: 111-119, 1997.
60. Nomoto M, Yamada K, Haga M, Hayashi M: Improvement of intestinal absorption of peptide drugs by glycosylation: transport of tetrapeptide by the sodium ion dependent D-glucose transporter. J Pharm Sci 87: 326-332, 1998.
61. Kramer W, Wess G, Enhsen A, Falk E, Hoffmann A et al.: Modified bile acids as carriers for peptides and drugs. J Controlled Release 46: 17-30, 1997.
62. Swaan PW, Szoka FC, Oie S: Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv Drug Delivery Rev 20: 59-82, 1996.
63. Russell-Jones GJ: Use of vitamin B12 conjugates to deliver protein drugs by the oral route. Crit Rev Ther Drug Carrier Syst 15: 557-586, 1998.
64. Shah D, Shen WC: Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J Pharm Sci 85: 1306-1311, 1996.
65. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A et al.: Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J Pharm Sci 86: 1016-1021, 1997.
66. Tozaki H, Fujita T, Odoriba T, Terabe A, Suzuki T et al.: Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: Therapeutic effects against 2,4,6-trinitrobenzene sulphonic acid-induced ulcerative colitis in rats. Life Sci 64: 1155-1162, 1999.
67. Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H et al.: Colon-specific delivery of budesonide with azopolymer-coated pellets: Therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol 51: 257-261, 1999.
68. Tozaki H, Fujita T, Odoriba T, Terabe A, Okabe S et al.: Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol 51: 1107-1112, 1999.
69. Yamamoto A, Tozaki H, Okada N, Fujita T: Colon-specific delivery of peptide drugs and anti-inflammatory drugs using chitosan capsules. STP Pharma Sciences 10: 23-34, 2000.
70. Tozaki H, Nishioka J, Komoike J, Okada N, Fujita T et al.: Enhanced absorption of insulin and (Asul.7)eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J Pharm Sci 90: 89-97, 2001.
71. Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A et al.: Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Controlled Release 82: 51-61, 2002.
72. Fetih G, Lindberg S, Itoh K, Okada N, Fujita T et al.: Improvement of absorption enhancing effects of n-dodecyl-β-D-maltopyranoside by its colon-specific delivery using chitosan capsules. Int J Pharm 293: 127-135, 2005.
73. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F et al.: A new approach to the oral administration of insulin and other peptide drugs. Science 233: 1081-1084, 1986.
74. Suzuki A, Morishita M, Kajita M, Takayama K, Isowa K et al.: Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid. J Pharm Sci 87: 1196-1202, 1998.
75. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y: Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 13: 896-901, 1996.
76. Iwanaga K, Ono S, Narioka K, Morimoto K, Kakemi M et al.: Oral delivery of insulin by using surface coating Liposomes. Improvement of stability of insulin in GI tract. Int J Pharm 157: 73-80, 1997.
77. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K et al.: Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm 149: 93-106. 1997.
78. Damge C, Vranckx H, Balschmidt P, Couvreur P: Poly (alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 86: 1403-1409, 1997.
79. Ohtani T, Murakami M, Yamamoto A, Takada K, Muranishi S: Effect of absorption enhancers on pulmonary absorption of fluorescein isothiocyanate dextrans with various molecular weights. Int J Pharm 77: 141-150, 1991.
80. Morita T, Yamamoto A, Hashida M, Sezaki H: Effects of various absorption promoters on pulmonary absorption of drugs with different molecular weights. Biol Pharm Bull 16: 259-262, 1993.
81. Yamamoto A, Morita T, Hashida M, Sezaki H: Effect of absorption promoters on the nasal absorption of drugs with various molecular weights. Int J Pharm 93: 91-99, 1993.
82. Yamamoto A, Umemori S, Muranishi S: Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J Pharm Pharmacol 46: 14-18, 1994.
83. Morita T, Yamamoto A, Takakura Y, Hashida M, Sezaki H: Improvement of the pulmonary absorption of (Asu1.7)-eelcalcitonin by various protease inhibitors in rats. Pharm Res 11: 909-913, 1994.
84. Fukuda Y, Tsuji T, Fujita T, Yamamoto A, Muranishi S: Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol Pharm Bull 18: 891-894, 1995.
85. Hanatani K, Takada K, Yoshida N, Nakasuji M, Morishita Y et al.: Molecular weight-dependent lymphatic transfer of fluorescein isothiocyanate-labeled dextrans after intrapulmonary administration and effects of various absorption enhancers on the lymphatic transfer of drugs in rats. J Drug Targeting 3: 263-271, 1995.
86. Yamamoto A, Fujita T, Muranishi S: Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors. J Controlled Release 41: 57-67, 1996.
87. Okumura S, Fukuda Y, Takahashi K, Fujita T, Yamamoto A et al.: Transport of drugs across the Xenopus pulmonary membrane and their absorption enhancement by various absorption enhancers: Pharm Res 13: 1247-1251, 1996.
88. Okumura S, Tanaka H, Shinsako K, Ito M, Yamamoto A et al.: Evaluation of drug absorption after intrapulmonary administration using Xenopus pulmonary membranes: correlation with in vivo pulmonary absorption studies in rats. Pharm Res 14: 1282-1285, 1997.
89. Yamamoto A, Okumura S, Fukuda Y, Fukui M, Takahashi K et al.: Improvement of the pulmonary absorption of (Asu1.7)-eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J Pharm Sci 86: 1144-1147. 1997.
90. Yamamoto A, Iseki T, Ochi-Sugiyama M, Okada N, Fujita T et al.: Absorption of water-soluble compounds with different molecular weights and (Asu1.7)-eel calcitonin from various mucosal administration sites. J Controlled Release 76: 363-374, 2001.
91. Yamamoto A, Yamada K, Muramatsu H, Nishinaka A, Okumura S et al.: Control of pulmonary absorption of water-soluble compounds by various viscous vehicles. It J Pharm 282: 141-149, 2004.
92. Yamada K, Kamada N, Odomi M, Okada N, Nabe T: Carageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retiontion in the lung tissues without any membrane damage. Int J Pharm 293: 63-72, 2005.
93. Yamada K, Odomi M, Okada N, Fujita T, Yamamoto A: Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon-α in rats. J Pharm Sci, 2005, (in press).